The EU decision: Our strategy continues

On the 23rd June 2016 the UK voted to leave the European Union (EU). We do not yet know how this will affect our community. There are a number of possible next steps and we are sure that it will take many months before we can comment definitively on what will happen in terms of provision of NHS treatment and care and research.

As we said in our position statement in the run-up to the referendum, EU funding for scientific research in the UK is significant. We do not know whether this funding will still be made available in the UK following the Leave vote.

We do not yet know how the decision to exit the EU will affect pan-European clinical trials or NHS staffing levels (currently around 5% of NHS staff come from other EU countries).

Whatever the impact of this vote, we will continue to work tirelessly to ensure that our strategic goals are met. Where possible we will collaborate across the globe to fund the highest quality research into better treatments for brain tumours.

We will work with other organisations across the UK, Europe and the rest of the world in order to make the changes that are needed to improve the lives of all those affected by the disease. We are committed to a world where brain tumours are defeated.